Pharmacokinetics of liposomal aerosolized cyclosporine A for pulmonary immunosuppression

George V. Letsou, Hazim J. Safi, Michael J. Reardon, Mehmet Ergenoglu, Zheng Li, Christos N. Klonaris, John C. Baldwin, Brian E. Gilbert, John C. Waldrep

Research output: Contribution to journalArticlepeer-review

40 Scopus citations


Background. The results of pulmonary transplantation are compromised by acute and chronic rejection. We hypothesized that a liposomal form of aerosolized cyclosporine A (CsA) would be selectively deposited and concentrated in the lungs. The theoretical advantage of this therapy is selective pulmonary immunosuppression with prolonged utilization. Methods. Eighteen dogs were endotracheally intubated; aerosolized liposomal CsA was administered for 15 min. CsA levels were measured in whole blood, lung, trachea, heart, kidney, liver, and spleen at various times after treatment. Results. The lung rapidly absorbs aerosolized liposomal CsA; other organs have much lower concentrations. The retention of pulmonary CsA delivered by liposome aerosol is approximately 120 min in this model. Conclusions. Aerosolized liposomal CsA is selectively deposited and concentrated in the lungs; other organs absorb less CsA.

Original languageEnglish (US)
Pages (from-to)2044-2048
Number of pages5
JournalAnnals of Thoracic Surgery
Issue number6
StatePublished - Dec 1999

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Pharmacokinetics of liposomal aerosolized cyclosporine A for pulmonary immunosuppression'. Together they form a unique fingerprint.

Cite this